Recombinant adeno-associated virus vectors.

@article{Hallek1998RecombinantAV,
  title={Recombinant adeno-associated virus vectors.},
  author={Michael J Hallek and Anne Girod and Markus Braun-Falco and Clemens Martin Wendtner and C. Bogedain and M H{\"o}rer},
  journal={IDrugs : the investigational drugs journal},
  year={1998},
  volume={1 5},
  pages={561-73}
}
Recombinant adeno-associated virus (rAAV) is a promising vector for somatic gene therapy due to the ability to transduce terminally-differentiated and non-dividing cells, the lack of any apparent pathogenicity, a low immunogenicity, a relatively high stability of transgene expression, and the potential for targeted integration. Improved methods of rAAV packaging allow the generation of concentrated and highly purified rAAV for clinical trials. Preclinical studies with rAAV are currently in… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

Similar Papers

Loading similar papers…